Assessment of lipid response to acute olanzapine administration in healthy adults.
atypical antipsychotics
dopamine
lipid metabolism
olanzapine
Journal
Endocrinology, diabetes & metabolism
ISSN: 2398-9238
Titre abrégé: Endocrinol Diabetes Metab
Pays: England
ID NLM: 101732442
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
27
12
2019
revised:
04
02
2020
accepted:
09
02
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
23
4
2020
Statut:
epublish
Résumé
Atypical antipsychotics (AAP) can induce hypertriglyceridaemia and type 2 diabetes. Weight gain contributes to these effects, but there is evidence that AAP can have acute metabolic effects on glycaemia independent of weight change. We undertook a single-blind crossover study in eight healthy volunteers to assess whether the AAP olanzapine acutely increases triglyceride and free fatty acid in response to a high-fat oral load (50 g fat with no carbohydrate) and whether these effects are attenuated by the dopamine D2 receptor agonist bromocriptine. Participants underwent three treatments in random order: Olanzapine 10 mg plus placebo (OL + PL), Olanzapine 10 mg plus bromocriptine 5 mg (OL + BR) and placebo plus placebo (PL + PL). Olanzapine increased plasma prolactin, an effect that was reversed by co-administration of the D2 receptor agonist bromocriptine ( These results suggest that AAPs likely do not directly increase postprandial lipids but may do so indirectly via changes in body weight and/or glycaemia.
Sections du résumé
BACKGROUND
BACKGROUND
Atypical antipsychotics (AAP) can induce hypertriglyceridaemia and type 2 diabetes. Weight gain contributes to these effects, but there is evidence that AAP can have acute metabolic effects on glycaemia independent of weight change.
AIMS
OBJECTIVE
We undertook a single-blind crossover study in eight healthy volunteers to assess whether the AAP olanzapine acutely increases triglyceride and free fatty acid in response to a high-fat oral load (50 g fat with no carbohydrate) and whether these effects are attenuated by the dopamine D2 receptor agonist bromocriptine.
METHODS
METHODS
Participants underwent three treatments in random order: Olanzapine 10 mg plus placebo (OL + PL), Olanzapine 10 mg plus bromocriptine 5 mg (OL + BR) and placebo plus placebo (PL + PL).
RESULTS
RESULTS
Olanzapine increased plasma prolactin, an effect that was reversed by co-administration of the D2 receptor agonist bromocriptine (
CONCLUSION
CONCLUSIONS
These results suggest that AAPs likely do not directly increase postprandial lipids but may do so indirectly via changes in body weight and/or glycaemia.
Identifiants
pubmed: 32318637
doi: 10.1002/edm2.119
pii: EDM2119
pmc: PMC7170459
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e00119Informations de copyright
© 2020 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
SD has received consulting fees and speaker fees from Eli Lilly and Novo Nordisk.
Références
J Clin Psychiatry. 2010 Sep;71(9):1205-11
pubmed: 20441717
J Clin Endocrinol Metab. 2003 Dec;88(12):5875-80
pubmed: 14671184
Am J Physiol Endocrinol Metab. 2011 Sep;301(3):E429-46
pubmed: 21693689
Am J Clin Nutr. 1994 Apr;59(4):853-60
pubmed: 8147330
CNS Drugs. 2005;19 Suppl 1:1-93
pubmed: 15998156
J Clin Psychopharmacol. 2013 Dec;33(6):740-6
pubmed: 24100786
Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):460-6
pubmed: 20717020
Diabetes Care. 2000 Aug;23(8):1154-61
pubmed: 10937514
Int J Neuropsychopharmacol. 2012 Mar;15(2):163-79
pubmed: 21854679
Physiol Rev. 2007 Apr;87(2):507-20
pubmed: 17429039
J Lipid Res. 1990 Apr;31(4):597-602
pubmed: 2351868
Schizophr Res. 2009 Mar;108(1-3):127-33
pubmed: 19157785
J Clin Endocrinol Metab. 2002 Jun;87(6):2918-23
pubmed: 12050274
Diabetes Care. 2011 Apr;34(4):789-94
pubmed: 21447659
Obesity (Silver Spring). 2010 Aug;18(8):1646-51
pubmed: 20134408
J Clin Endocrinol Metab. 2010 Jan;95(1):118-25
pubmed: 19906788
Neuropsychopharmacology. 2008 Jun;33(7):1633-41
pubmed: 17712347
Am J Clin Nutr. 1988 Oct;48(4):1031-4
pubmed: 3048075